Dylan Erdle is CenExel’s Chief Strategy & Corporate Development Officer. In this role, Dylan leads strategic growth initiatives and mergers & acquisitions efforts across the organization.
 
For the 10 years prior to joining CenExel, Dylan invested in pharma services companies across the healthcare and life sciences landscape, including leading site networks, CROs, specialty pharmaceutical companies, and clinical trial technology organizations, among others. His experience has centered on strategic growth initiatives, transaction execution, governance, and M&A within the pharma services sector.
 
Earlier in his career, Dylan served on the leveraged buyouts team at H.I.G. Capital, where he focused on transaction execution, financing, and portfolio company oversight. He earned a Bachelor of Science degree from the McIntire School of Commerce at the University of Virginia and an MBA from the Wharton School of the University of Pennsylvania.